Emma O Billington1,2, Andrew Grey3, Mark J Bolland3. 1. Division of Endocrinology, University of Calgary, Calgary, Canada. e.billington@auckland.ac.nz. 2. Bone & Joint Research Group, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1010, New Zealand. e.billington@auckland.ac.nz. 3. Bone & Joint Research Group, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1010, New Zealand.
Abstract
AIMS/HYPOTHESIS: Thiazolidinediones (TZDs) are associated with an increased risk of fracture but the mechanism is unclear. We sought to determine the effect of TZDs on bone mineral density (BMD) and bone turnover markers. METHODS: PubMed, EMBASE and Cochrane CENTRAL databases were searched from inception until January 2015 for randomised controlled trials comparing TZDs with metformin, sulfonylureas or placebo, and those reporting changes in BMD and/or bone turnover markers. The primary outcome was percentage change in BMD from baseline and results were pooled with random effects meta-analyses. RESULTS: In all, 18 trials were included in the primary analyses and another two were included in the sensitivity analyses (n = 3,743, 50% women, mean age 56 years, median trial duration 48 weeks). TZDs decreased BMD at the lumbar spine (difference -1.1% [95% CI -1.6, -0.7]; p < 0.0001), total hip (-1.0% [-1.4, -0.6]; p < 0.0001) and forearm (-0.9% [-1.6, -0.3]; p = 0.007). There were statistically non-significant decreases in BMD at the femoral neck (-0.7% [-1.4, 0.0]; p = 0.06) and total body (-0.3% [-0.5, 0.0]; p = 0.08). Five trials (n = 450) showed no statistically significant difference in percentage change in BMD between the TZD group and controls up to 1 year following TZD withdrawal. In 14 trials, the effect of TZD treatment on turnover markers varied considerably between individual studies. CONCLUSIONS/ INTERPRETATION: Treatment with TZDs results in modest bone loss that may not be reversed 1 year after cessation of treatment.
AIMS/HYPOTHESIS: Thiazolidinediones (TZDs) are associated with an increased risk of fracture but the mechanism is unclear. We sought to determine the effect of TZDs on bone mineral density (BMD) and bone turnover markers. METHODS: PubMed, EMBASE and Cochrane CENTRAL databases were searched from inception until January 2015 for randomised controlled trials comparing TZDs with metformin, sulfonylureas or placebo, and those reporting changes in BMD and/or bone turnover markers. The primary outcome was percentage change in BMD from baseline and results were pooled with random effects meta-analyses. RESULTS: In all, 18 trials were included in the primary analyses and another two were included in the sensitivity analyses (n = 3,743, 50% women, mean age 56 years, median trial duration 48 weeks). TZDs decreased BMD at the lumbar spine (difference -1.1% [95% CI -1.6, -0.7]; p < 0.0001), total hip (-1.0% [-1.4, -0.6]; p < 0.0001) and forearm (-0.9% [-1.6, -0.3]; p = 0.007). There were statistically non-significant decreases in BMD at the femoral neck (-0.7% [-1.4, 0.0]; p = 0.06) and total body (-0.3% [-0.5, 0.0]; p = 0.08). Five trials (n = 450) showed no statistically significant difference in percentage change in BMD between the TZD group and controls up to 1 year following TZD withdrawal. In 14 trials, the effect of TZD treatment on turnover markers varied considerably between individual studies. CONCLUSIONS/ INTERPRETATION: Treatment with TZDs results in modest bone loss that may not be reversed 1 year after cessation of treatment.
Authors: M Alexandra Sorocéanu; Dengshun Miao; Xiu-Ying Bai; Hanyi Su; David Goltzman; Andrew C Karaplis Journal: J Endocrinol Date: 2004-10 Impact factor: 4.286
Authors: S Benvenuti; I Cellai; P Luciani; C Deledda; S Baglioni; C Giuliani; R Saccardi; B Mazzanti; S Dal Pozzo; E Mannucci; A Peri; M Serio Journal: J Endocrinol Invest Date: 2007-10 Impact factor: 4.256
Authors: G A Bray; S R Smith; M A Banerji; D Tripathy; S C Clement; T A Buchanan; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R E Ratner; D C Schwenke; F B Stentz; P D Reaven; R A DeFronzo Journal: Diabetes Obes Metab Date: 2013-05-07 Impact factor: 6.577
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: Lancet Date: 2009-06-06 Impact factor: 79.321
Authors: Astrid K Stunes; Irene Westbroek; Björn I Gustafsson; Reidar Fossmark; Jan H Waarsing; Erik F Eriksen; Christiane Petzold; Janne E Reseland; Unni Syversen Journal: BMC Endocr Disord Date: 2011-05-26 Impact factor: 2.763
Authors: S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: Joseph M Rutkowski; Johanne Pastor; Kai Sun; Sun K Park; I Alexandru Bobulescu; Christopher T Chen; Orson W Moe; Philipp E Scherer Journal: Kidney Int Date: 2016-11-30 Impact factor: 10.612
Authors: Catherine M Viscoli; Silvio E Inzucchi; Lawrence H Young; Karl L Insogna; Robin Conwit; Karen L Furie; Mark Gorman; Michael A Kelly; Anne M Lovejoy; Walter N Kernan Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958